Fingolimod Therapy for Pediatric Relapsing-Remitting Multiple Sclerosis: A Real-Life Study

Ilki C. D., Gunduz T., Kurtuncu M., Yapici Z., Sencer S., Eraksoy M.

TURKISH JOURNAL OF NEUROLOGY, vol.26, no.1, pp.34-38, 2020 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 26 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.4274/tnd.galenos.2019.77010
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.34-38
  • Istanbul University Affiliated: Yes


Objective: Clinical studies in childhood multiple sclerosis (MS) are very limited compared with adults. Although first-line injection therapies are well tolerated in this patient group, there are difficulties in the long-term treatment of patients due to the difficulty and adverse effects of injections for children. Oral therapies are better tolerated for use and adverse effects compared with injection therapies. This study aimed to evaluate the clinical features and treatment outcomes of patients aged under 18 years with relapsing-remitting MS (RAMS) who received fingolimod treatment.